MedTrace Logo

Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

NCT04930627 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-06-23

No results posted yet for this study

Summary

Treatment of neutropenia of Glycogenosis type 1b patients with empagliflozin

Conditions

  • Glucose 6 Phosphatase Deficiency

Interventions

DRUG

Empagliflozin

dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg

Sponsors & Collaborators

  • Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw

    collaborator UNKNOWN

  • Children's Memorial Health Institute, Poland

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2024-06-30
Completion
2025-03-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930627 on ClinicalTrials.gov